RKVTF (Rakovina Therapeutics) LT-Debt-to-Total-Asset: 0.72 (As of Mar. 2026)


RKVTF Rakovina Therapeutics Inc RKVTF
32 GF Score
Price $0.09
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics LT-Debt-to-Total-Asset?

Rakovina Therapeutics RKVTF 32 LT-Debt-to-Total-Asset is 0.72 as of Mar. 2026. GuruFocus rates RKVTF with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rakovina Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.72.

Rakovina Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.72). It may suggest that Rakovina Therapeutics is progressively becoming more dependent on debt to grow their business.

Rakovina Therapeutics  (OTCPK:RKVTF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rakovina Therapeutics LT-Debt-to-Total-Asset Related Terms

Rakovina Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Rakovina Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics LT-Debt-to-Total-Asset Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.00 0.00 0.26 0.00 0.27

Rakovina Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.17 0.22 0.27 0.72
RKVTF
32GF Score
Rakovina Therapeutics Inc RKVTF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics LT-Debt-to-Total-Asset Calculation

Rakovina Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.834/3.074
=

Rakovina Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=2.192/3.059
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.72 mean?
Rakovina Therapeutics (RKVTF) has a LT-Debt-to-Total-Asset of 0.72 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rakovina Therapeutics and its competitors.
Is Rakovina Therapeutics' LT-Debt-to-Total-Asset too high?
Rakovina Therapeutics' current LT-Debt-to-Total-Asset is 0.72. Overall, Rakovina Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Rakovina Therapeutics' LT-Debt-to-Total-Asset of 0.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rakovina Therapeutics and its competitors. Rakovina Therapeutics's current LT-Debt-to-Total-Asset is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current LT-Debt-to-Total-Asset of 0.72. The current LT-Debt-to-Total-Asset is 0.72. Rakovina Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current LT-Debt-to-Total-Asset is 0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
32GF Score

Get the complete analysis for RKVTF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price